了解细胞因子释放综合征。 - Suppr

Understanding cytokine release syndrome.

作者信息

Gödel Philipp, Shimabukuro-Vornhagen Alexander, von Bergwelt-Baildon Michael

机构信息

Intensive Care Unit and Interventional Immunology Cologne, Department I of Internal Medicine, University of Cologne, Cologne, Germany.

出版信息

Intensive Care Med. 2018 Mar;44(3):371-373. doi: 10.1007/s00134-017-4943-5. Epub 2017 Sep 27.

DOI:10.1007/s00134-017-4943-5

PMID:28956093

Abstract

摘要

相似文献

Understanding cytokine release syndrome.

Intensive Care Med. 2018 Mar;44(3):371-373. doi: 10.1007/s00134-017-4943-5. Epub 2017 Sep 27.

How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response.

Cytokine. 2013 Oct;64(1):471-2. doi: 10.1016/j.cyto.2013.07.009. Epub 2013 Jul 30.

Response to the letter to the editor by Susan Thorpe et al.: how predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response.

Cytokine. 2013 Oct;64(1):473-5; discussion 476. doi: 10.1016/j.cyto.2013.07.014. Epub 2013 Aug 3.

A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.

Cytokine. 2012 Dec;60(3):828-37. doi: 10.1016/j.cyto.2012.08.018. Epub 2012 Sep 15.

Cytokine release syndrome: Who is at risk and how to treat.

Best Pract Res Clin Haematol. 2017 Dec;30(4):336-340. doi: 10.1016/j.beha.2017.09.002. Epub 2017 Sep 22.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.

Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.

Immunotherapy. 2017 Mar;9(4):309-311. doi: 10.2217/imt-2016-0134.

Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.

Melanoma Res. 2015 Apr;25(2):178-9. doi: 10.1097/CMR.0000000000000132.

Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.

Int Immunopharmacol. 2011 Nov;11(11):1697-705. doi: 10.1016/j.intimp.2011.06.001. Epub 2011 Jun 29.

Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.

Neurosurg Clin N Am. 2010 Jan;21(1):67-76. doi: 10.1016/j.nec.2009.08.010.

引用本文的文献

Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Front Oncol. 2025 Aug 13;15:1575376. doi: 10.3389/fonc.2025.1575376. eCollection 2025.

Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report.

Curr Oncol. 2025 Aug 18;32(8):469. doi: 10.3390/curroncol32080469.

Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications.

Arch Clin Cases. 2025 Jul 15;12(2):98-101. doi: 10.22551/2025.47.1202.10320. eCollection 2025.

Deep insight into cytokine storm: from pathogenesis to treatment.

Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.

Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.

World J Clin Cases. 2024 Dec 16;12(35):6782-6790. doi: 10.12998/wjcc.v12.i35.6782.

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.

J Immunother Cancer. 2024 Aug 13;12(8):e009475. doi: 10.1136/jitc-2024-009475.

Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.

Cancer Rep (Hoboken). 2024 Jul;7(7):e2145. doi: 10.1002/cnr2.2145.

Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.

Immunotherapy. 2024;16(12):791-801. doi: 10.1080/1750743X.2024.2370180. Epub 2024 Jul 17.

Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies.

J Transl Med. 2024 Jul 2;22(1):613. doi: 10.1186/s12967-024-05308-2.

Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes.

Clin Kidney J. 2024 May 30;17(6):sfae123. doi: 10.1093/ckj/sfae123. eCollection 2024 Jun.

本文引用的文献

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.

Immunotherapeutic implications of IL-6 blockade for cytokine storm.

Immunotherapy. 2016 Jul;8(8):959-70. doi: 10.2217/imt-2016-0020.

Critical care of patients with cancer.

CA Cancer J Clin. 2016 Nov 12;66(6):496-517. doi: 10.3322/caac.21351. Epub 2016 Jun 27.

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20.

Toxicities of chimeric antigen receptor T cells: recognition and management.

Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.

Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.

Eur J Haematol. 2015 Jun;94(6):554-7. doi: 10.1111/ejh.12396. Epub 2014 Jul 2.

Current concepts in the diagnosis and management of cytokine release syndrome.

Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Understanding cytokine release syndrome.

作者信息

Gödel Philipp, Shimabukuro-Vornhagen Alexander, von Bergwelt-Baildon Michael

机构信息

Intensive Care Unit and Interventional Immunology Cologne, Department I of Internal Medicine, University of Cologne, Cologne, Germany.

出版信息

Intensive Care Med. 2018 Mar;44(3):371-373. doi: 10.1007/s00134-017-4943-5. Epub 2017 Sep 27.

DOI:10.1007/s00134-017-4943-5

PMID:28956093

Abstract

摘要

相似文献

Understanding cytokine release syndrome.

Intensive Care Med. 2018 Mar;44(3):371-373. doi: 10.1007/s00134-017-4943-5. Epub 2017 Sep 27.

How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response.

Cytokine. 2013 Oct;64(1):471-2. doi: 10.1016/j.cyto.2013.07.009. Epub 2013 Jul 30.

Cytokine. 2013 Oct;64(1):473-5; discussion 476. doi: 10.1016/j.cyto.2013.07.014. Epub 2013 Aug 3.

A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.

Cytokine. 2012 Dec;60(3):828-37. doi: 10.1016/j.cyto.2012.08.018. Epub 2012 Sep 15.

Cytokine release syndrome: Who is at risk and how to treat.

Best Pract Res Clin Haematol. 2017 Dec;30(4):336-340. doi: 10.1016/j.beha.2017.09.002. Epub 2017 Sep 22.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.

Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.

Immunotherapy. 2017 Mar;9(4):309-311. doi: 10.2217/imt-2016-0134.

Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.

Melanoma Res. 2015 Apr;25(2):178-9. doi: 10.1097/CMR.0000000000000132.

Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.

Int Immunopharmacol. 2011 Nov;11(11):1697-705. doi: 10.1016/j.intimp.2011.06.001. Epub 2011 Jun 29.

Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.

Neurosurg Clin N Am. 2010 Jan;21(1):67-76. doi: 10.1016/j.nec.2009.08.010.

引用本文的文献

Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Front Oncol. 2025 Aug 13;15:1575376. doi: 10.3389/fonc.2025.1575376. eCollection 2025.

Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report.

Curr Oncol. 2025 Aug 18;32(8):469. doi: 10.3390/curroncol32080469.

Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications.

Arch Clin Cases. 2025 Jul 15;12(2):98-101. doi: 10.22551/2025.47.1202.10320. eCollection 2025.

Deep insight into cytokine storm: from pathogenesis to treatment.

Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.

Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.

World J Clin Cases. 2024 Dec 16;12(35):6782-6790. doi: 10.12998/wjcc.v12.i35.6782.

J Immunother Cancer. 2024 Aug 13;12(8):e009475. doi: 10.1136/jitc-2024-009475.

Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.

Cancer Rep (Hoboken). 2024 Jul;7(7):e2145. doi: 10.1002/cnr2.2145.

Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.

Immunotherapy. 2024;16(12):791-801. doi: 10.1080/1750743X.2024.2370180. Epub 2024 Jul 17.

Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies.

J Transl Med. 2024 Jul 2;22(1):613. doi: 10.1186/s12967-024-05308-2.

Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes.

Clin Kidney J. 2024 May 30;17(6):sfae123. doi: 10.1093/ckj/sfae123. eCollection 2024 Jun.

本文引用的文献

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.

Immunotherapeutic implications of IL-6 blockade for cytokine storm.

Immunotherapy. 2016 Jul;8(8):959-70. doi: 10.2217/imt-2016-0020.

Critical care of patients with cancer.

CA Cancer J Clin. 2016 Nov 12;66(6):496-517. doi: 10.3322/caac.21351. Epub 2016 Jun 27.

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Blood. 2016 Jun 30;127(26):3312-20. doi: 10.1182/blood-2016-02-629063. Epub 2016 May 20.

Toxicities of chimeric antigen receptor T cells: recognition and management.

Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.

Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.

Eur J Haematol. 2015 Jun;94(6):554-7. doi: 10.1111/ejh.12396. Epub 2014 Jul 2.

Current concepts in the diagnosis and management of cytokine release syndrome.

Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

Understanding cytokine release syndrome.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Understanding cytokine release syndrome.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献